A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Status:
Completed
Trial end date:
2021-09-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and
tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor
telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with
advanced/metastatic solid tumors.